Today, Celmatix, the next-generation womens health company, announced the initial findings of two landmark research studies that shed new light on biomarkers that are related to a womans fertility and her ovarian reserve. These studies are among the largest ever aimed at understanding ovarian reserve and its role in regulating the so-called biological clock. Celmatix presented the findings during two scientific sessions at the American Society of Reproductive Medicine (ASRM) annual meeting this week in Denver, Colorado.
Over time, a womans ovarian reserve gradually depletes, and continues to do so until menopause. It is generally accepted that a womans fertility starts to decline more rapidly in her mid-30s, but in reality, each womans experience is different. As more and more women across the world wait until later in life to have children, it is becoming increasingly critical for women to gain a deeper understanding of their ovarian reserve and how it may impact their fertility. The new studies presented this week by Celmatix are exemplary of this desperately needed research.
The first study, Premature Menopause Genome-wide Association Study in 75,000 Women of European Ancestry, conducted in collaboration with personal genetics company 23andMe Inc, is the largest to date to examine the genomic factors associated with premature menopause, a condition that affects approximately one in 100 women. This case-control genome-wide association study (GWAS) utilizing data from 75,000 23andMe customers consented for research, confirmed an association between genes involved in cellular quality control and a DNA damage checkpoint with early menopause in women of European ancestry and suggested that many loci associated with age of menopause are also associated with premature menopause.
The second study, also the largest of its kind, Decreased Ovarian Reserve Biomarkers are Associated with Reduced Fecundability in Women with No History of Infertility, established an association between biomarkers including anti-M¼llerian hormone (AMH), basal antral follicle count (BAFC), and day three follicle-stimulating hormone (FSH) and reduced fecundability in women seeking intrauterine insemination with donor sperm (DIUI) as a proxy to the general population. In the wake of recent studies questioning the utility of AMH testing as an indication of future fertility in women without a history of infertility, these initial findings shed new light on the complexity of the issue.
For years, weve been at the precipice of a shift towards consumer-driven scientific research, powered by the massive stores of data volunteered through genetic testing or health-tracking apps, said Dr. Piraye Yurttas Beim, founder and CEO of Celmatix. Until now, we havent really seen the payoff in womens reproductive health, but these studies exemplify how thats starting to change. With this new research, were gaining unprecedented clarity into one of the most fundamental factors affecting womens fertility, and, as a result, offering women and their doctors a more solid foundation from which to make informed decisions about their care and family building.
For more information on Celmatix and its research, visit www.celmatix.com/research.
About Celmatix Inc.
Celmatix is a next-generation womens health company transforming reproductive health care through genomics and big data. Founded in 2009 and based in New York City, Celmatix is disrupting how women approach their lifelong fertility journey by empowering them and their physicians with more personalized information. The companys research-driven products include the Fertilome test, the worlds first multigene panel test that reveals what a womans DNA says about her reproductive health, Polaris, a real-time predictive analytics platform in use at leading fertility clinics across the U.S., which helps physicians optimize patient outcomes and improve the patient experience, and MyFertility Compass„¢, a data-driven education tool that gives women who are currently trying to conceive insights into their fertility potential.
Margaret Farrell, (203) 434-2240